Concurrent Session: New Paradigm for Analytical Methods - ICH Q2(R2) & Q14

Date
November 1, 2022

Concurrent Session: New Paradigm for Analytical Methods - ICH Q2(R2) & Q14 | In the first quarter of 2022 drafts of ICH Q2(R2) and Q14 were released for public comment. This is the first time there have been significant changes to the guidance for analytical methods since the release of Q2 in the 1990's. Stop and think for a moment how much change there has been in the past several decades. The speed of development has increased, the diversity of therapeutic products has changed, and the technology employed (including use of multivariate methods) to test these materials has continued to evolve. This session will bring together the opinions of thought leaders in this area (EWG industry, EWG regulatory, and the practitioner) to share their perspectives and lead a discussion on the new operating system that is possible given the new draft ICH guidelines. Presentations will be followed by a roundtable/panel discussion to address questions and obtain feedback on the guidance documents (including implementation and case studies) and/or solicit input on any available feedback from the EWG.

Speakers

Speaker Image for Christine Moore
Executive Director, Quality Systems & Compliance, Organon LLC
Speaker Image for Raphael Sanches Pereira
Health Regulation and Surveillance Specialist, Anvisa
Speaker Image for Bryan Castle
Associate Vice President - Synthetic Molecule Design & Development, Eli LIlly & Company
Speaker Image for Jayda Siggers
Senior Scientific Evaluator, Health Canada
Speaker Image for Nina Cauchon
Director Regulatory Affairs - CMC, Amgen Inc.

Related Products

Thumbnail for ICH Q12 Implementation Progress and Future Opportunities
ICH Q12 Implementation Progress and Future Opportunities
ICH Q12 is a truly transformational guideline that has a wide scope of applicability across the pharmaceutical development lifecycle and can help streamline the post-approval change management process by promoting the adoption of flexible science- and risk-based approaches…
Thumbnail for Concurrent Session: Building a Quality Organization
Concurrent Session: Building a Quality Organization
Concurrent Session: Building a Quality Organization | While pharmaceutical GMPs and their associated guidelines recommend a quality unit that is independent of the manufacturing unit, they give little or no information on its organizational construct…
Thumbnail for Modernizing Regulatory CMC Submissions: Enabling Change
Modernizing Regulatory CMC Submissions: Enabling Change
The session will discuss the current challenges of static and unstructured PDF-based CMC regulatory submissions for drug applications and the modernization efforts of utilizing structured data for regulatory CMC submissions…
Thumbnail for Concurrent Session: Drug Shortages: Progress in a Challenging Year
Concurrent Session: Drug Shortages: Progress in a Challenging Year
Concurrent Session: Drug Shortages: Progress in a Challenging Year | As we enter a transitional period within the pandemic, some uncertainties remain. The need to continually improve supply chain resiliency remains certain, as demonstrated by the challenges with Single Use Systems…